seralutinib
seralutinib: developed by 1 company · 3 clinical trials tracked.
seralutinib evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could seralutinib → GOSS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
Clinical Trials (3)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Followed by a Long-Term Extension Evaluating Safety and Efficacy
Primary endpoint: Change in distance achieved on the six-minute walk test (6MWT), from baseline to PCP Week 24
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)
Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
Primary endpoint: Change in distance achieved on the six-minute walk test (6MWT), six-minute walk distance (Δ6MWD) from baseline to Week 24
Frequently asked questions
Who is developing seralutinib?
seralutinib is being developed by Gossamer Bio, Inc..
How many clinical trials involve seralutinib?
BioSniper tracks 3 clinical trials involving seralutinib.